{"name":"PLx Pharma","slug":"plx-pharma","ticker":"","exchange":"","domain":"","description":"","hq":"Houston","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":753108,"revenueGrowth":-3.3,"grossMargin":0,"rdSpend":4182000,"netIncome":-46125000,"cash":76642000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2018"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"cardiovascular","drugs":[{"name":"Enteric-coated aspirin caplets","genericName":"Enteric-coated aspirin caplets","slug":"enteric-coated-aspirin-caplets","indication":"Cardiovascular event prevention (secondary prevention of myocardial infarction and stroke)","status":"phase_3"},{"name":"Immediate-Release Aspirin Tablets","genericName":"Immediate-Release Aspirin Tablets","slug":"immediate-release-aspirin-tablets","indication":"Cardiovascular event prevention (secondary prevention post-myocardial infarction or stroke)","status":"phase_3"},{"name":"PL-ASA","genericName":"PL-ASA","slug":"pl-asa","indication":"Cardiovascular event prevention in patients at risk for aspirin-related gastrointestinal bleeding","status":"marketed"},{"name":"PL2200 Aspirin Capsules","genericName":"PL2200 Aspirin Capsules","slug":"pl2200-aspirin-capsules","indication":"Cardiovascular event prevention in patients at risk for aspirin-related gastrointestinal complications","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"PL 3100","genericName":"PL 3100","slug":"pl-3100","indication":"Other","status":"phase_1"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Aspirin tablets","genericName":"Aspirin tablets","slug":"aspirin-tablets","indication":"Acute myocardial infarction (secondary prevention)","status":"marketed"}]}],"pipeline":[{"name":"PL 3100","genericName":"PL 3100","slug":"pl-3100","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Aspirin tablets","genericName":"Aspirin tablets","slug":"aspirin-tablets","phase":"marketed","mechanism":"Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of prostaglandins and thromboxane to provide anti-inflammatory, analgesic, and antiplatelet effects.","indications":["Acute myocardial infarction (secondary prevention)","Ischemic stroke and transient ischemic attack (secondary prevention)","Stable and unstable angina","Mild to moderate pain","Fever"],"catalyst":""},{"name":"Enteric-coated aspirin caplets","genericName":"Enteric-coated aspirin caplets","slug":"enteric-coated-aspirin-caplets","phase":"phase_3","mechanism":"Aspirin inhibits platelet aggregation by irreversibly acetylating cyclooxygenase (COX) enzymes, reducing thromboxane A2 production and preventing clot formation.","indications":["Cardiovascular event prevention (secondary prevention of myocardial infarction and stroke)","Primary prevention of cardiovascular disease in high-risk patients"],"catalyst":""},{"name":"Immediate-Release Aspirin Tablets","genericName":"Immediate-Release Aspirin Tablets","slug":"immediate-release-aspirin-tablets","phase":"phase_3","mechanism":"Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes to reduce platelet aggregation and inflammation.","indications":["Cardiovascular event prevention (secondary prevention post-myocardial infarction or stroke)","Pain and fever relief","Inflammatory conditions"],"catalyst":""},{"name":"PL-ASA","genericName":"PL-ASA","slug":"pl-asa","phase":"marketed","mechanism":"PL-ASA is a combination formulation of aspirin with a protective coating designed to reduce gastrointestinal irritation and bleeding risk while maintaining antiplatelet efficacy.","indications":["Cardiovascular event prevention in patients at risk for aspirin-related gastrointestinal bleeding"],"catalyst":""},{"name":"PL2200 Aspirin Capsules","genericName":"PL2200 Aspirin Capsules","slug":"pl2200-aspirin-capsules","phase":"phase_3","mechanism":"PL2200 is a modified-release aspirin formulation designed to reduce gastrointestinal irritation while maintaining antiplatelet efficacy.","indications":["Cardiovascular event prevention in patients at risk for aspirin-related gastrointestinal complications","Secondary prevention of myocardial infarction and stroke"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNcWFNQ0pSdUxxcDZJenJ6TVZNY2tCYmZjTG8ybXJ4Z3NQYUF4ekRIMzFEeEp2aERTTXJVZTFRb3B5eTdOanY5NWlpa3loX21ZenRVcTNHTmxZWUhMa3p3VGtfYll0M01ua0RmVF9PYnBSaU9TYVozNjVPeTN2VUViNXJuSGNiRlZpdHJsb0ZWZVZaUzIyYS1wVWx2VmQydFZKbXdoX0loSmpHNnFDdWRmbA?oc=5","date":"2026-04-05","type":"pipeline","source":"The Chronicle-Journal","summary":"Vaccinex, Inc. - Common Stock (NQ: VCNX - The Chronicle-Journal","headline":"Vaccinex, Inc. - Common Stock (NQ: VCNX - The Chronicle","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPbFRVWXoyYXRVaTB5MUtfbE5tYVh5LUQ5eHlfRjJyaUtROTRNTGJXOWtoZktLZThSQk1sREhBc21vR0hZOGZ2U0ttUHVYS0pXVG1VaS1PMG53Vm9mMTRWYVNrdDhHUHA3ck83Z2RHM0RHVkxjX1hEUGZQay1ZQjJxVGppZG9Tc092dkFQREJpbjd6T2xMa2tSdVFIQkY1RnFFOVFpeHFkNVNQRWJHYzBRbGUzRXdkdnJyMVBBZkV4UTQ?oc=5","date":"2026-03-17","type":"pipeline","source":"professional.heart.org","summary":"Medical Marijuana, Recreational Cannabis, and Cardiovascular Health - professional.heart.org","headline":"Medical Marijuana, Recreational Cannabis, and Cardiovascular Health","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxQUzNEVTQ5RWJSblEybmR5TjRtT0w0SEJqVm03WWttQ1JKSjJSUExlSjByQmtXV1VBZEZhMXpGNFJxVm9FVW1rTTdKVkZBM3Z3QVdnaTJoMndTMzZ2Mmg2UFJQMmxQNk11ampjTHdsb3dIMUlZRmhWblVpUEVBd2hEYnVES0JEMko0a0VPaTMxenc5aE9LelB2VTM2SU1GSm1ZaGFNNkpXZEpfZUFwaHNCUEhxVTJPanIxaWQxYTRHMnYtQlVraldrcjd0LTBRbjdlVjZ5NGJPTGVpNmRtZnBsalMzS0doZmtaWTN1MFd3UDN4bi0yVlNCbVpFSm4yQV9kR0ZBeGkxbWxDZk5YZWp4NVl1Qi0zaE0?oc=5","date":"2026-02-02","type":"pipeline","source":"TradingView","summary":"Polaryx Therapeutics, Clinical-Stage Developer of Therapies for Lysosomal Storage Disorders, Files for Nasdaq Capital Market IPO - TradingView","headline":"Polaryx Therapeutics, Clinical-Stage Developer of Therapies for Lysosomal Storage Disorders, Files for Nasdaq Capital Ma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBFdC10dmcyR2RnTjE5RGg2UXloaFFxZ1kyYTJ5LUFxd0NPejgzcHVTc19FMzJ2MXZrZnhRYjQwYXFxcDBBV2l3cG8ya0pIaDgxRDFR?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"PLXP Stock Price, News & Analysis - Stock Titan","headline":"PLXP Stock Price, News & Analysis","sentiment":"neutral"},{"date":"2023-09-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2023-08-22","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2023-07-21","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2023-07-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2023-07-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2023-06-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2023-05-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2023-04-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2023-04-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2023-04-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2023-04-06","type":"earnings","source":"SEC EDGAR","summary":"SC 13G filed with SEC","headline":"SC 13G Filing","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_1":1,"marketed":2,"phase_3":3},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":753108,"revenuePeriod":"2018-12-31","revenueHistory":[{"value":753108,"period":"2018-12-31"},{"value":778657,"period":"2017-12-31"},{"value":778657,"period":"2017-12-31"},{"value":0,"period":"2016-12-31"},{"value":20000,"period":"2016-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":4182000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-46125000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":76642000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}